You are being redirected to another site.
The Recent Developments in Gene Targeted and Immunotherapies of Parkinson Disease webinar will review the current state of affairs of clinical trials of both these types of therapies. The lectures will cover the pharmacology and recent results of relevant clinical trials, as well as their future directions.The treatment of Parkinson’s disease (PD) has thus far been restricted to symptomatic therapies. These treatments improve quality of life but do not address PD’s relentless progression. The discovery of genetic mutations that cause or increase the risk of development of PD has opened the possibility of genetically targeted therapies with the potential of slowing or stopping the progression of specific monogenetic forms of PD. Further, the possibility that misfolded synuclein aggregation is a key pathogenetic factor in PD has culminated in ongoing trials of synuclein-targeted immunotherapies with a similar potential benefit for all forms of PD, be they genetic or sporadic.
Carlos Singer, MD - University of Miami, Miami, FL, USARoy N. Alcalay, MD - Columbia University Medical Center, New York, NY, USAJoseph Quinn, MD - Oregon Health and Sciences University, Portland, OR, USA
The primary purpose of this program is to provide information on gene therapy.
Upon completion of this activity learners will be able to:1. Describe the different mechanisms of action of the gene and synuclein targeted therapies of PD2. Explain the current state of development of clinical trials of both therapies3. Recognize the use of biomarkers to monitor target engagement and effect on progression of PD4. Identify future directions of these novel therapeutic modalities
This activity is intended for neurologists interested or specializing in Movement Disorders.
The course must be attended in their entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.
GENE20WEB-Disc
The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.2. Compatible with Windows PC and MAC (256 MB of RAM or higher)3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher4. Adobe Flash Player 12.0 (or higher). 5. Adobe Reader to print certificate.
MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
All individuals in control of content for this course are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME.